PMID- 18433349
OWN - NLM
STAT- MEDLINE
DCOM- 20080715
LR  - 20191110
IS  - 1742-5255 (Print)
IS  - 1742-5255 (Linking)
VI  - 4
IP  - 4
DP  - 2008 Apr
TI  - Pantoprazole: from drug metabolism to clinical relevance.
PG  - 471-83
LID - 10.1517/17425255.4.4.471 [doi]
AB  - BACKGROUND: Conditions requiring inhibition of acid secretion, such as 
      gastro-oesophageal reflux disease (GORD), peptic ulcers, non-ulcer dyspepsia or 
      the use of NSAIDs, are very common, and their prevalence is expecting to rise as 
      they are seen predominantly amongst the elderly. Among the drugs available to 
      inhibit acid secretion, proton pump inhibitors (PPI) have been shown to have the 
      best efficacy-safety ratio and have been used widely. OBJECTIVE: This paper was 
      intended to provide an overall presentation of one of these PPIs, pantoprazole. 
      METHOD: This study was first intended to give an overview of pantoprazole, so a 
      Medline search was conducted using pantoprazole as unique search term, without 
      publication date restriction. We found 826 references for pantoprazole and 
      selected some of the most relevant publications to conduct this review. 
      RESULTS/CONCLUSION: Five different PPIs are commercially available: omeprazole, 
      pantoprazole, rabeprazole, lansoprazole and esomeprazole. Pantoprazole differs 
      from other PPIs by a selective binding to the ion transport pathway, a good 
      stability at neutral pH values, and a relatively robust plasma concentration-time 
      curve. These pharmacokinetic differences may not be fully converted into 
      pharmacodynamic differences of pantoprazole versus other PPIs. Pantoprazole has 
      been assessed in most of the clinical situations where acid suppression is 
      required, and showed great efficacy and an excellent safety profile. Some safety 
      concerns were raised with long-term use of PPIs, but they are well balanced by 
      the benefit of PPIs for patients with conditions such as GORD or peptic ulcer.
FAU - Bardou, Marc
AU  - Bardou M
AD  - Centre d'Investigations Cliniques, CHU de Dijon, France. 
      Marc.Bardou@u-bourgogne.fr
FAU - Martin, Janet
AU  - Martin J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - D8TST4O562 (Pantoprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/metabolism/*therapeutic use
MH  - Anti-Ulcer Agents/metabolism/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Gastroesophageal Reflux/drug therapy
MH  - Humans
MH  - Pantoprazole
MH  - Peptic Ulcer/drug therapy
MH  - Proton Pump Inhibitors/metabolism/*therapeutic use
MH  - Treatment Outcome
RF  - 75
EDAT- 2008/04/25 09:00
MHDA- 2008/07/17 09:00
CRDT- 2008/04/25 09:00
PHST- 2008/04/25 09:00 [pubmed]
PHST- 2008/07/17 09:00 [medline]
PHST- 2008/04/25 09:00 [entrez]
AID - 10.1517/17425255.4.4.471 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):471-83. doi: 
      10.1517/17425255.4.4.471.